For years, the Research Triangle—anchored by Raleigh, Durham, and Chapel Hill—has been a quiet powerhouse in biotech. Its strength has long been evident in the numbers: North Carolina ranks third nationally for life sciences employment, with more than 75,000 workers, and hosts a concentration of NIH funding, academic research output, and biomanufacturing capacity unmatched outside of Boston or the Bay Area. But if talent, science, and infrastructure were already in place, capital has always been the missing piece.
That picture may now be shifting.
Two announcements this summer point to a new chapter in the Triangle’s ascent as a biotech investment hub. Durham-based Hatteras Venture Partners, the region’s best-known life sciences venture firm, closed more than $200 million across two new funds—its largest haul in a quarter century. Meanwhile, Cape Fear BioCapital, a new entrant dedicated exclusively to seed-stage therapeutics in North Carolina, deployed its first investments into Duke spinouts. Together, they signal not just momentum, but a maturing investment climate that could reshape the state’s innovation trajectory.
Hatteras: Scaling While Others Retreat
Hatteras’s announcement comes against a difficult macro backdrop. Venture funding for healthcare startups has slumped, with just $5 billion raised in the first half of 2025, compared with $23 billion across all of 2024, according to PitchBook. In that context, Hatteras’s ability to secure $177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund is a striking display of investor confidence.
As co-founder Clay Thorp told The Wall Street Journal, “In this environment, we feel fantastic about how we’re positioned.” (WSJ)
That positioning is the product of nearly three decades of early-stage focus, with Hatteras supporting more than 100 companies since inception. The firm’s strategy—identifying startups built on “transformative science” emerging from academia and seed-stage entrepreneurs—has produced a stable of companies ranging from AI-driven drug discovery players like Ten63 Therapeutics to oncology innovators like Kymera Therapeutics.
The real differentiator, however, isn’t just check size but operational value. As Ten63 CEO Marcel Frenkel put it, “It’s a group that brings much more than cash.”
That reputation makes Hatteras a gravitational anchor for other investors considering the region. In a market where capital is scarce and cautious, its success suggests that limited partners still view the Triangle as one of the best places to find defensible, science-driven innovation.
Hatteras’s portfolio shows that roughly a third of its tracked investments—15 out of 42—are in the Southeast, with many clustered around North Carolina’s Research Triangle. That regional weighting is unusual for a national-scale life sciences fund and underscores the firm’s longstanding commitment to seeding and scaling innovation close to home.
Cape Fear: Filling the Seed-Stage Gap
While Hatteras strengthens later early-stage and Series A+ companies, Cape Fear BioCapital was launched to plug what its founders call the “valley of death” in regional funding—the lack of capital at the pre-seed and seed stages.
Founded in 2024 by industry veterans Ed Field, Jimmy Melton, and Dave Ousterout, the fund is laser-focused: therapeutics startups in North Carolina that can advance to an IND in roughly three years. With support from Moore Strategic Ventures, Cape Fear intends to back 8–10 startups through its Fund I, with plans for a $100 million Fund II.
As Field explained when announcing the fund, “Our region has an abundance of life sciences innovation… but without early-stage funding many of our best opportunities will not be realized.” (Cape Fear BioCapital)
He pointed out that only 1 percent of venture capital deployed in North Carolina goes to seed or pre-seed companies—a stark mismatch with the density of academic research and entrepreneurial activity in the state.
Cape Fear is already acting on its thesis. In June 2025, the firm invested in Ten63 Therapeutics and Thoracic Therapeutics, two Duke-affiliated startups developing AI-enabled drug discovery and novel pulmonary disease therapies, respectively (Triangle Business Journal). For a fund that launched less than a year ago, it’s an early validation of both the pipeline and the firm’s intention to keep capital anchored locally.
A More Complete Capital Stack for NC Startups
Taken together, these developments are more than two fund announcements. They represent the scaffolding of a more complete capital stack within North Carolina:
- Cape Fear BioCapital feeding the pipeline at the seed stage.
- Hatteras Venture Partners bridging to growth, with decades of credibility and operational depth.
- Other active funds such as Pappas Capital, NovaQuest, and Alexandria Seed Capital rounding out the mix.
This layered capital environment reduces the pressure for promising founders to leave the state in search of capital, a trend that has historically drained talent and IP to Boston or San Diego. Instead, North Carolina may now be on the cusp of retaining more of its innovation and converting it into high-growth companies headquartered in the state.
It also sends a signal to global pharma: the Triangle isn’t just a site for large-scale manufacturing investments (such as Biogen’s $2 billion expansion and Genentech’s $700 million Holly Springs site), but also a fertile ground for early science translation. That creates a flywheel effect, where research, startups, capital, and industry scale reinforce each other.
What It Means for the Innovation Climate
- Investor Confidence Amid Uncertainty: Hatteras’s raise shows that seasoned VCs see opportunity in the Triangle even during a downturn.
- Closing the Seed Gap: Cape Fear’s local-first mandate addresses a structural weakness in the ecosystem, one that has held back university spinouts and first-time founders.
- Strategic Momentum: With state-backed institutions like the North Carolina Biotechnology Center and nonprofits like the Burroughs Wellcome Fund also deploying resources, the ecosystem is aligning across public, private, and philanthropic capital.
- National Relevance: For LPs and entrepreneurs evaluating alternatives to Boston or the Bay, these moves make a compelling case that North Carolina is now a tier-one innovation hub in formation.
Active Life Sciences Funders in the Triangle
- Hatteras Venture Partners – $200M across two funds (2025), 100+ portfolio companies.
- Cape Fear BioCapital – Seed-stage therapeutics fund, launched 2024, already investing locally.
- Pappas Capital – RTP-based, global biotech and medtech focus.
- NovaQuest Capital Management – Raleigh-based, mid-stage and growth equity for biotech and pharma.
- Bull City Venture Partners – Early-stage Southeast investor, healthtech included.
- IDEA Fund Partners – Durham-based seed fund, strong ties to university spinouts.
- Excelerate Health Ventures – Healthcare IT and SaaS focus.
- SJF Ventures – Growth-stage impact investor, headquartered in Durham.
- Aurora Funds – Broad healthcare and IT venture backing.
- InterSouth Partners – Longstanding Triangle investor in life sciences and tech.
- Alexandria Venture Investments / Seed Capital – RTP-based, tied to Alexandria LaunchLabs.
- RTP Angel Fund / RTP Capital – Angel groups targeting early-stage NC ventures.
- VentureSouth – Southeastern angel network, active in NC.
- Burroughs Wellcome Fund – RTP nonprofit grantmaker, $40M+ annually.
- North Carolina Biotechnology Center (NCBiotech) – State-backed nonprofit, $187M+ invested since inception.
Bottom line: North Carolina’s Research Triangle isn’t just attracting capital—it’s building a layered investment infrastructure that could make it one of the most competitive regions for life sciences innovation in the country.
